Log in

EIB grants 20 M EUR loan to biotech Da Volterra

The European Investment Bank (EIB) has granted 20 million euros to the French biotech Da Volterra to accelerate its clinical development program aimed at antibiotic resistance infections.

This program concerns "the prevention and treatment of serious infectious diseases and nosocomial diseases in a context related to resistance to antibiotics", explain the EIB and Da Volterra in a joint statement on Friday.

"This EIB loan is up to the challenge posed by multi-resistant bacteria and the many infectious risks today," said Da Volterra President, Florence Séjourné, quoted in the statement.

The company's most advanced product, DAV132, is developed to prevent infections with Clostridium difficile bacteria and the emergence of resistant bacteria in at-risk patients through an innovative mechanism of action that protects intestinal flora from damage of antibiotics.

EIB financing for the development of Da Volterra is part of the Horizon 2020 initiative of the European Commission.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P